Drug Manufacture Progress in MorphoSys’ Phase 3 Myelofibrosis Program.By MohamedMis2July 17, 2023 MorphoSys, the German biotech company, has delivered positive news to its shareholders. The Phase 3 myelofibrosis program is progressing 16%…
